Insights

Growing Presence Orphazyme has a strategic expansion with offices in Denmark, Switzerland, and the US, indicating increased global outreach and potential for partnerships across diverse markets.

Niche Focus Specialized in neurodegenerative orphan diseases with a late-stage pipeline, Orphazyme presents opportunities to collaborate on rare disease treatments targeting specialized healthcare providers and research institutions.

Recent Asset Sales The company sold assets worth $12.8 million to Zevra Therapeutics and KemPharm, aligning with their shift towards becoming a more focused, commercially-driven rare disease therapeutics entity, which could open doors for licensing and joint ventures.

Funding & Revenue With funding of $109 million and minimal revenue, there is potential for sales efforts geared towards investors and partners interested in the company’s promising pipeline and upcoming commercial initiatives.

Leadership Changes New CEO Anders Vadsholt’s appointment, along with leadership transitions, suggest a phase of strategic realignment, creating opportunities to engage with company executives on partnership developments or strategic collaborations.

Orphazyme A/S Tech Stack

Orphazyme A/S uses 8 technology products and services including Font Awesome, Google Cloud, jQuery UI, and more. Explore Orphazyme A/S's tech stack below.

  • Font Awesome
    Font Scripts
  • Google Cloud
    Infrastructure As A Service
  • jQuery UI
    Javascript Libraries
  • Underscore.js
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Yoast SEO
    Search Engines
  • Twitter
    Widgets

Media & News

Orphazyme A/S's Email Address Formats

Orphazyme A/S uses at least 1 format(s):
Orphazyme A/S Email FormatsExamplePercentage
First.Last@orphazyme.comJohn.Doe@orphazyme.com
90%
Last@orphazyme.comDoe@orphazyme.com
10%

Frequently Asked Questions

Where is Orphazyme A/S's headquarters located?

Minus sign iconPlus sign icon
Orphazyme A/S's main headquarters is located at Denmark. The company has employees across 2 continents, including EuropeNorth America.

What is Orphazyme A/S's phone number?

Minus sign iconPlus sign icon
You can contact Orphazyme A/S's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Orphazyme A/S's stock symbol?

Minus sign iconPlus sign icon
Orphazyme A/S is a publicly traded company; the company's stock symbol is ORPHY.

What is Orphazyme A/S's official website and social media links?

Minus sign iconPlus sign icon
Orphazyme A/S's official website is orphazyme.com and has social profiles on LinkedIn.

What is Orphazyme A/S's SIC code NAICS code?

Minus sign iconPlus sign icon
Orphazyme A/S's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Orphazyme A/S have currently?

Minus sign iconPlus sign icon
As of December 2025, Orphazyme A/S has approximately 108 employees across 2 continents, including EuropeNorth America. Key team members include Executive Director, Payer Engagement: T. D.Statistics Specialist: T. H.: C. B.. Explore Orphazyme A/S's employee directory with LeadIQ.

What industry does Orphazyme A/S belong to?

Minus sign iconPlus sign icon
Orphazyme A/S operates in the Biotechnology Research industry.

What technology does Orphazyme A/S use?

Minus sign iconPlus sign icon
Orphazyme A/S's tech stack includes Font AwesomeGoogle CloudjQuery UIUnderscore.jsjQuery MigratejQueryYoast SEOTwitter.

What is Orphazyme A/S's email format?

Minus sign iconPlus sign icon
Orphazyme A/S's email format typically follows the pattern of First.Last@orphazyme.com. Find more Orphazyme A/S email formats with LeadIQ.

How much funding has Orphazyme A/S raised to date?

Minus sign iconPlus sign icon
As of December 2025, Orphazyme A/S has raised $109M in funding. The last funding round occurred on Feb 07, 2020 for $109M.

When was Orphazyme A/S founded?

Minus sign iconPlus sign icon
Orphazyme A/S was founded in 2009.

Orphazyme A/S

Biotechnology ResearchDenmark51-200 Employees

Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases.

Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our global presence with offices in Denmark, Switzerland, and our US headquarters in Chicago.

See our community guidelines: bit.ly/3uapRYr

Section iconCompany Overview

Headquarters
Denmark
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ORPHY
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $109M

    Orphazyme A/S has raised a total of $109M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2020 in the amount of $109M.

  • $1M

    Orphazyme A/S's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $109M

    Orphazyme A/S has raised a total of $109M of funding over 7 rounds. Their latest funding round was raised on Feb 07, 2020 in the amount of $109M.

  • $1M

    Orphazyme A/S's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.